Harpoon Therapeutics, Inc. (HARP) Financial Statements (2024 and earlier)

Company Profile

Business Address 611 GATEWAY BOULEVARD, SUITE 400
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:45,60061,38553,10066,10090,200112,500
Cash and cash equivalents32,79761,38551,61450,36868,56850,738
Short-term investments12,758 1,49815,73021,58561,727
Other undisclosed cash, cash equivalents, and short-term investments45 (12)24735
Other undisclosed current assets3,4672,4761,6273,0493,8374,445
Total current assets:49,06763,86154,72769,14994,037116,945
Noncurrent Assets
Operating lease, right-of-use asset9,29510,41110,8545,6195,7985,967
Property, plant and equipment3,6725,7577,2377,9178,2478,722
Other noncurrent assets1,165780911811869813
Total noncurrent assets:14,13216,94819,00214,34714,91415,502
TOTAL ASSETS:63,19980,80973,72983,496108,951132,447
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities18,01119,02919,07322,20923,74820,001
Employee-related liabilities3,9393,796
Accounts payable3,6274,0024,7122,6402,7904,189
Accrued liabilities14,38415,02714,36115,63017,16215,812
Deferred revenue 4,44822,35530,93733,96336,50436,875
Other undisclosed current liabilities2,8752,7892,423(2,111)(2,029)1,707
Total current liabilities:25,33444,17352,43354,06158,22358,583
Noncurrent Liabilities
Long-term debt and lease obligation:    9,1459,63210,094
Liabilities, other than long-term debt12,29130,67515,8973,37814,45422,386
Deferred revenue  2,3142,3143,37814,45422,386
Operating lease, liability12,29112,81613,5839,1459,63210,094
Derivative instruments and hedges, liabilities  15,545    
Other undisclosed noncurrent liabilities22,5765,246    
Total noncurrent liabilities:34,86735,92115,89712,52324,08632,480
Total liabilities:60,20180,09468,33066,58482,30991,063
Equity
Equity, attributable to parent2,9987155,39916,91226,64241,384
Common stock444444
Additional paid in capital365,790364,572357,921351,040349,158346,581
Accumulated other comprehensive income (loss)5 (3)(28)(56)(88)
Accumulated deficit(362,801)(363,861)(352,523)(334,104)(322,464)(305,113)
Total equity:2,9987155,39916,91226,64241,384
TOTAL LIABILITIES AND EQUITY:63,19980,80973,72983,496108,951132,447

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues20,2218,5834,08913,6178,3035,906
Gross profit:20,2218,5834,08913,6178,3035,906
Operating expenses(17,728)(19,348)(22,801)(25,506)(25,714)(26,219)
Operating income (loss):2,493(10,765)(18,712)(11,889)(17,411)(20,313)
Nonoperating income (expense)127(435)29324960(8)
Investment income, nonoperating61542534328910440
Other nonoperating income (expense)(488)(860)(50)(40)(44)(48)
Interest and debt expense(1,560)(138)    
Income (loss) from continuing operations:1,060(11,338)(18,419)(11,640)(17,351)(20,321)
Loss before gain (loss) on sale of properties:(11,640)(17,351)(20,321)
Net income (loss):1,060(11,338)(18,419)(11,640)(17,351)(20,321)
Other undisclosed net income attributable to parent 1     
Net income (loss) available to common stockholders, diluted:1,061(11,338)(18,419)(11,640)(17,351)(20,321)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net income (loss):1,060(11,338)(18,419)(11,640)(17,351)(20,321)
Other undisclosed comprehensive income   44   
Comprehensive income (loss):1,060(11,338)(18,375)(11,640)(17,351)(20,321)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent63(19)2832(41)
Comprehensive income (loss), net of tax, attributable to parent:1,066(11,335)(18,394)(11,612)(17,319)(20,362)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: